UNCY Stock Analysis: Buy, Sell, or Hold?
UNCY - Unicycive Therapeutics, Inc. Common Stock
$6.45
0.48 (8.04%)
▲
5d:
-6.25%
30d:
+11.79%
90d:
+34.1%
HOLD
LOW Confidence
Last Updated: February 2, 2026
Smart Money Accumulation
UNCY is down 6.2% this week, but smart money is accumulating calls. Top strike: $7.5 2026-03-20 with 6 OI. Call ratio: 100% View Scanner →
Strength: 8.1/10
Get Alerted When UNCY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called UNCY this week
50% bullish • 1 bearish
50% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: UNCY is fairly valued with market pricing in 2.0% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: UNCY is fairly valued with market pricing in 2.0% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$8.28
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$5.14
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: UNCY is currently trading at $6.45, which is considered slightly low relative to its 30-day fair value range of $5.73 to $6.71. The stock's valuation (Forward PE: 1.1) is in line with its historical norms (1.0). At these levels, the market is pricing in 2.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, UNCY is in a strong uptrend. Immediate support is located at $5.83, while resistance sits at $7.29. The stock is showing strong short-term momentum, up 8.0% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $46.50 (+620.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, UNCY is in a strong uptrend. Immediate support is located at $5.83, while resistance sits at $7.29. The stock is showing strong short-term momentum, up 8.0% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $46.50 (+620.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$5.73 -
$6.71
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
85.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.0%)
- BULLISH: Trading 620.9% below Wall St target ($46.50)
- NEUTRAL: Market pricing in 2.0% annual earnings growth - fairly valued
- CAUTION: Recommendation downgraded due to -6.2% 5-day decline
Fair Price Analysis
30-Day Fair Range
$5.73 -
$6.71
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$5.83
Resistance Level
$7.29
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
1.09
Wall Street Target
$46.50
(+620.9%)
Valuation Premium vs History
+2.0% premium
PE vs Historical
1.1 vs 1.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.0%
(market-implied from PE analysis)
1-Year Target
$6.58
(+2%)
2-Year Target
$6.71
(+4%)
3-Year Target
$6.84
(+6%)
3-Yr Target (if PE normalizes)
(PE: 1→1)
PE COMPRESSION
$6.27
(-3%)
Earnings growth offset by PE compression
Last updated: February 03, 2026 8:29 AM ET
Data refreshes hourly during market hours. Next update: 9:29 AM
Data refreshes hourly during market hours. Next update: 9:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UNCY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 48 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$215 | 53 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$277 | 62 BUY |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$31 | 59 HOLD |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
12 analysts |
$21 | 60 HOLD |
